For a decade, obesity medicines were judged against bariatric surgery. They got close enough that the comparison stopped being the point.
From Bariatric Benchmark to Pharmaceutical Reality
Bariatric surgery has a blunt kind of authority. A gastric bypass does not negotiate with a weekly injection schedule. It rearranges anatomy, and for years it sat at the top of every comparison table as the goal that obesity pharmacotherapies could not touch. The honest reading of the late twentieth and early twenty-first century was that this goal would continue to be unattainable. Drug developers were never expected to catch up to it with a peptide.
Then, in December 2014, they got a foothold. The US Food and Drug Administration approved liraglutide, already familiar at a lower dose on diabetes labels, for chronic weight management as an adjunct to reduced-calorie diet and increased physical activity.1 The molecule was not a revolution in chemistry so much as an admission that a glucagon-like peptide-1 (GLP-1) receptor agonist could be a weight-loss medicine at all. The SCALE study showed that an obesity-specific dose could produce clinically meaningful weight loss rather than a side effect borrowed from glycaemic control.2 Prior to this existed a proverbial graveyard of drug development failure that a later review would describe as modest mean losses, safety findings that ended programmes, a field littered with pharmacological bets that did not survive contact with patients.3
What followed was not a single leap. It was a decade of increments that, added together, did something that previously seemed implausible. Once-weekly semaglutide 2.4 mg, in the STEP 1 study in 2021, raised the ceiling of expectation for weight loss.4 Tirzepatide, in the SURMOUNT-1 study in 2022, raised it again.5 A survey of the next wave of multi-agonist GLP-1 medicines then put those magnitudes beside bariatric surgery, not as a claim that a pen is equivalent to an operation, but as a statement that mean percent weight loss is no longer the unachievable goal it was when liraglutide was the news.6 A review written while that wave was still gathering had already named surgery as the efficacy benchmark and warned that an operation cannot reach every patient in need. It also allowed that future pharmacological combinations might one day surpass it.7
Catching up with the weight loss impact of bariatric surgery, or even drawing level with its shadow, was supposed to be the destination. It was not. The SELECT study reduced major adverse cardiovascular events with semaglutide 2.4 mg in people who had preexisting cardiovascular disease and were overweight or obese but did not have diabetes.8 A simple scale cannot capture the significance of that result. It can only sit beside it, looking suddenly like a partial answer to a larger question. If an incretin can now move weight into the range of surgery and change the rate of heart attacks and strokes, then the finish line the field spent a decade chasing was never the whole course.
Obesity Is a Chronic Disease, Not a Cosmetic Condition
Something else was happening whilst increments in mean percent weight loss accumulated. In 2017 the World Obesity Federation described obesity as a chronic, relapsing, progressive disease process.9 That sentence is easy to quote and hard to live with. A chronic disease is not an episode you interrupt with a short course of a drug and then forget. It relapses. It progresses. It asks for maintenance, not a before-and-after photograph.
Regulators have begun to write that logic into the brief. The FDA’s 2025 draft guidance on drugs and biological products for weight reduction, still a draft, frames the aim as reduction and long-term maintenance of body weight.10 Diet and activity were never retired as the context of use; liraglutide was approved into them.1 The 2026 pharmacological framework from the European Association for the Study of Obesity goes further in a different direction. It matches medicines to complication domains rather than ranking them by mean percent weight loss.11 The implied question is not which drug subtracts the most weight, but which part of the disease a given molecule is for.
The pressure is not only focused on adults. Adolescent obesity already carries serious morbidity into young adulthood, as observed in some cohorts within just a few years of follow-up.12 Developers who treat children and adolescents as a later chapter are writing as if the disease waits politely for an eighteenth birthday. It does not. A chronic disease that starts early is a different planning problem from a chronic disease that is allowed to look, on a label, like a cosmetic episode in midlife.
None of this cancels the importance of the kilogram or the pound. It relocates it. Once obesity is named as a disease of organs and decades, a trial whose only decisive sentence is a mean percent weight loss starts to look like a study of one downstream number. The number still has to move, and it is no longer allowed to be the only thing that does.
Beyond the Scale: Measuring Tissue Health
Tissue is where the new finishing line of the weight-loss argument is being redrawn. When energy intake falls, fat mass falls and so does lean mass. That is physiology, not a special vice of incretins, and it is why “quality of loss” has become a phrase of increased importance. Dual-energy X-ray absorptiometry, the composition tool most programmes reach for, sorts a body into two bins: fat, and everything else, labelled lean. Lean, in that vocabulary, is a mixture. Water, viscera, bone mineral, and contractile skeletal muscle can all recede, and the instrument will still report a tidy two-part success.
An exploratory DXA analysis from the STEP 1 programme found lean body mass falling about 9.7% from baseline even as the proportion of lean mass rose, a reminder that absolute loss and compositional share are different facts.13 A DXA substudy from the SURMOUNT-1 programme found that of the weight lost on tirzepatide, about 75% was fat and 25% was lean, a split that was similar on placebo in that analysis and is not a verdict that the drug uniquely dissolves muscle.14 The question those two-bin numbers cannot answer is whether the muscle change is adaptive or maladaptive. Magnetic resonance imaging can resolve muscle volume and intramuscular fat; DXA cannot. Imaging-informed primers treat lean-mass change as adaptive when volume tracks the weight that was lost and muscle quality, including fat infiltration, improves. Older and prefrail patients are the caveat, and deserve special attention because of the relative impact on morbidity.15
A second tissue story runs in parallel and is easier to miss because it does not show up in kilograms at all. Metaflammation is a name for the chronic, metabolically driven, low-grade inflammation that links adipose immune remodelling to insulin resistance and organ injury.16 Weight loss and weight cycling can leave unexpected, sometimes persistent marks on adipose immune populations.17 Kilograms or pounds can recede while inflammatory tone only partly remits, so two people with similar weight-loss percentages can walk out of a trial carrying different residual risk, and a development programme that only counted the percentages will not know which is which.
This is the other finish line, hiding inside the first. Improving weight loss without improving tissue health across the body is a partial result. Quantifying the therapeutic impact on fat relative to muscle, and on residual inflammatory tone, is no longer an exploratory goal. Those are now measures of whether a chronic, multisystem disease actually moved.
The Next Generation of Incretin Therapies
Demand for wider accessibility has pulled incretin chemistry into a second problem. Injectable GLP-1 agonists work. They also ask a person to stay on an injection, which is a real barrier, and the industry’s answer has been to get the agonist into a tablet. Oral semaglutide is still a peptide. It crosses the gastric epithelium with the enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a transcellular, pH-buffered, formulation-dependent route that looks nothing like a subcutaneous depot.18 Orforglipron, tested as a daily oral small molecule, is not a peptide at all.19 The receptor named on the drug label is unchanged. The laboratory problem is not.
Pharmacokinetic and immunogenicity methods built for a weekly injection do not transfer, unchanged, to either of those products. A peptide that must be absorbed in the stomach, and a small molecule that was never a peptide, generate different questions about exposure and about antibodies. If oral delivery is meant to widen who can use the medicine, those methods have to be built for the new route, or the dataset will not be interpretable.
The agonists also acquired extra peptide sequences. Mono-agonists became dual and triple agonists, and combinations added amylin, because more than one hormone sits on the path from gut to appetite to energy expenditure. A phase 2 trial of retatrutide, a triple-hormone-receptor agonist, put mean losses into the mid-twenties of percent.20 Extra sequence is how the field is now competing: a 2025 systematic review of emerging pharmacotherapies found 36 emerging agents or combinations across 53 trials, with completed phase 2 incretin mean losses already spanning 7.4% to 24.2%.21 Homology with more than one native hormone is not a trivia of sequence. It changes what an immunogenicity finding might mean. Drug-antibody binding is a laboratory observation. Neutralisation of one of several intended pathways, or a change in how the drug is cleared in people who carry that antibody, is a pharmacological one. A pooled analysis of phase 3 tirzepatide studies in type 2 diabetes found treatment-emergent antibodies in 51.1% of treated patients and no measurable effect on pharmacokinetics or efficacy.22 The rate was not the result that mattered. What the antibodies did, and did not do, was.
The same evolution that added sequence also added questions the old weight-loss trial was not built to ask. Muscle quality wants imaging that can see contractile muscle, not only a lean bin, and it wants to know whether circulating markers moved with the scan. Residual inflammation wants markers of immune tone, not a second weigh-in. None of that is a shopping list. It is what happens when the molecule and the disease both outgrow percent weight loss.
Defining Differentiation in a Crowded Obesity Market
A finish line that was measured against an operation made sense when pharmacological obesity interventions could not reach it. It makes less sense now that incretins have approached it, regulators have named a chronic disease, and the pipeline is full of programmes trying to prove, again, that an incretin can move a scale. The pipeline review is a picture of crowding.21 The European framework is a picture of how a crowded field is asked to choose: by complication, not by a leaderboard of weight lost.11 Bariatric surgery remains the historical benchmark, and it still cannot treat everyone who needs it,7 which is precisely why a tablet or a pen that merely copies the kilogram result of the last approved incretin is a weak claim to distinction.
The goalposts have moved, and they were moved by clinicians, by a society that can now see obesity as a disease of children as well as of midlife, and by regulators who want maintenance, lifestyle in the frame, and benefit that is not only the scale. Weight loss is still on the field. Muscle and inflammation have joined it. Developers who keep aiming at the posts as they stood in 2014, or even in 2021, are preparing a product for a contest that is no longer being held. In a landscape this competitive, a differentiated medicine is the one that can show what happened after the weight has been moved. That is not a scientific courtesy to be reported in the literature. It is the condition on which a crowded field will decide what is worth paying for.
About Synexa Life Sciences
As obesity drug development moves beyond weight loss, Synexa Life Sciences helps sponsors measure what comes next. Our expertise in bioanalysis, immunogenicity, biomarkers, inflammation, metabolism and tissue health enables the generation of robust data that supports differentiation, regulatory decision-making and clinical value across obesity programmes.
Visit https://synexagroup.com/expertise/obesity to learn more.
References
1. U.S. Food and Drug Administration. Drugs@FDA: SAXENDA (liraglutide) injection. NDA 206321 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321
2. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22 https://doi.org/10.1056/NEJMoa1411892
3. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223 https://doi.org/10.1038/s41573-021-00337-8
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002 https://doi.org/10.1056/NEJMoa2032183
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216 https://doi.org/10.1056/NEJMoa2206038
6. Xu Y, Drucker DJ, Traverso G, Beloqui A. Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies. Endocr Rev. 2026;47(1):1-23 https://doi.org/10.1210/endrev/bnaf027
7. Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery? Pharmacol Ther. 2023;250:108549 https://doi.org/10.1016/j.pharmthera.2023.108549
8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232 https://doi.org/10.1056/NEJMoa2307563
9. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723 https://doi.org/10.1111/obr.12551
10. U.S. Food and Drug Administration. Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction. Draft guidance for industry. 2025 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction
11. Ciudin A, Baker JL, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update. Nat Med. 2026;32(6):1962-1966 https://doi.org/10.1038/s41591-026-04397-4
12. Fliss Isakov N, Balmakov Y, Grinshpan LS, et al. Adolescent obesity and risk of serious chronic morbidity and mortality in young adulthood: a systematic review of cohorts from national registries. Cardiovasc Diabetol. 2026;25:213 https://doi.org/10.1186/s12933-026-03221-0
13. Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Suppl 1):A16-A17 https://doi.org/10.1210/jendso/bvab048.030
14. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729 https://doi.org/10.1111/dom.16275
15. Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150(16):1288-1298 https://doi.org/10.1161/CIRCULATIONAHA.124.067676
16. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-185 https://doi.org/10.1038/nature21363
17. Schleh MW, Caslin HL, Garcia JN, et al. Metaflammation in obesity and its therapeutic targeting. Sci Transl Med. 2023;15(723):eadf9382 https://doi.org/10.1126/scitranslmed.adf9382
18. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(444):eaar7047 https://doi.org/10.1126/scitranslmed.aar7047
19. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888 https://doi.org/10.1056/NEJMoa2302392
20. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526 https://doi.org/10.1056/NEJMoa2301972
21. Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002 https://doi.org/10.1124/pharmrev.123.001045
22. Mullins GR, Hodsdon ME, Li YG, et al. Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies. J Clin Endocrinol Metab. 2024;109(2):361-369 https://doi.org/10.1210/clinem/dgad532
Obesity FAQs
1. Why are incretin therapies changing obesity drug development?
Incretin therapies such as semaglutide and tirzepatide have achieved levels of weight loss previously associated with bariatric surgery, allowing researchers to focus on broader clinical outcomes beyond weight reduction.
2. Why is weight loss no longer enough as a clinical endpoint?
Regulators and clinicians increasingly view obesity as a chronic disease affecting multiple organ systems. This means therapies are now being assessed against cardiovascular outcomes, long-term maintenance, muscle health and inflammation, not simply body weight.
3. What will differentiate future obesity therapies?
Future therapies will likely be distinguished by their ability to demonstrate meaningful benefits across disease complications, tissue health, metabolic outcomes and long-term patient management rather than by weight loss alone.
